Ocular Therapeutix, Inc (OCUL) · Oct 16, 2026 · Exec change

Ocular Therapeutix executive change hits before AXPAXLI NDA filing

CSO departure

Ocular Therapeutix loses its chief strategy officer as AXPAXLI approaches a planned NDA submission, creating a fresh strategic leadership gap.

Ocular Therapeutix is transitioning from a DEXTENZA commercial base toward a retina-focused growth story led by AXPAXLI, with the company targeting a U.S. NDA submission for wet AMD in the fourth quarter of 2026.

The strategic leadership seat is now vacant at a sensitive point in that transition. Chief Strategy Officer Sanjay Nayak is leaving effective October 16, 2026 to become CEO of a private company. 〔0〕

This is more consequential than a routine executive reshuffle, but not a pipeline setback by itself. Nayak is not the CEO or chief development officer, and the filing gives no indication that AXPAXLI’s clinical, regulatory, or NDA plans have changed. The immediate effect is a newly created strategic-execution gap just as the company moves toward a major regulatory milestone; no successor or transition plan is disclosed.

Bottom line: The filing adds leadership uncertainty to an already milestone-driven AXPAXLI story, without changing the program’s stated regulatory trajectory. It matters, but mainly as an execution and continuity issue rather than evidence of a program setback.

Original filing on SEC EDGAR

Ocular Therapeutix executive change hits before AXPAXLI NDA filing | OCUL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.